These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 33373369)

  • 1. Differential effects of novel kappa opioid receptor antagonists on dopamine neurons using acute brain slice electrophysiology.
    Margolis EB; Wallace TL; Van Orden LJ; Martin WJ
    PLoS One; 2020; 15(12):e0232864. PubMed ID: 33373369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons.
    Margolis EB; Hjelmstad GO; Bonci A; Fields HL
    J Neurosci; 2003 Nov; 23(31):9981-6. PubMed ID: 14602811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
    Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
    J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two delta opioid receptor subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor.
    Margolis EB; Fujita W; Devi LA; Fields HL
    Neuropharmacology; 2017 Sep; 123():420-432. PubMed ID: 28645621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Navacaprant, a novel and selective kappa opioid receptor antagonist, has no agonist properties implicated in opioid-related abuse.
    Morrison FG; Van Orden LJ; Zeitz K; Kuijer EJ; Smith SL; Heal DJ; Wallace TL
    Neuropharmacology; 2024 Oct; 257():110037. PubMed ID: 38876309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mu/delta Cooperativity and opposing kappa-opioid effects in nucleus accumbens-mediated antinociception in the rat.
    Schmidt BL; Tambeli CH; Levine JD; Gear RW
    Eur J Neurosci; 2002 Mar; 15(5):861-8. PubMed ID: 11906528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct inhibition of hypothalamic proopiomelanocortin neurons by dynorphin A is mediated by the μ-opioid receptor.
    Pennock RL; Hentges ST
    J Physiol; 2014 Oct; 592(19):4247-56. PubMed ID: 25085890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. κ-Opioid Receptor Activation in Dopamine Neurons Disrupts Behavioral Inhibition.
    Abraham AD; Fontaine HM; Song AJ; Andrews MM; Baird MA; Kieffer BL; Land BB; Chavkin C
    Neuropsychopharmacology; 2018 Jan; 43(2):362-372. PubMed ID: 28649993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons.
    Ehrich JM; Messinger DI; Knakal CR; Kuhar JR; Schattauer SS; Bruchas MR; Zweifel LS; Kieffer BL; Phillips PE; Chavkin C
    J Neurosci; 2015 Sep; 35(37):12917-31. PubMed ID: 26377476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. General, kappa, delta and mu opioid receptor antagonists mediate feeding elicited by the GABA-B agonist baclofen in the ventral tegmental area and nucleus accumbens shell in rats: reciprocal and regional interactions.
    Miner P; Shimonova L; Khaimov A; Borukhova Y; Ilyayeva E; Ranaldi R; Bodnar RJ
    Brain Res; 2012 Mar; 1443():34-51. PubMed ID: 22305145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid-sensitive GABA inputs from rostromedial tegmental nucleus synapse onto midbrain dopamine neurons.
    Matsui A; Williams JT
    J Neurosci; 2011 Nov; 31(48):17729-35. PubMed ID: 22131433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrophysiological demonstration of mu, delta and kappa opioid receptors in the ventral pallidum.
    Mitrovic I; Napier TC
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1260-70. PubMed ID: 7891342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kappa1- and kappa2-opioid receptors mediating presynaptic inhibition of dopamine and acetylcholine release in rat neostriatum.
    Schoffelmeer AN; Hogenboom F; Mulder AH
    Br J Pharmacol; 1997 Oct; 122(3):520-4. PubMed ID: 9351509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies.
    Devine DP; Leone P; Pocock D; Wise RA
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1236-46. PubMed ID: 7690399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastric effects of mu-, delta- and kappa-opioid receptor agonists on brainstem unitary responses in the neonatal rat.
    Yuan CS
    Eur J Pharmacol; 1996 Oct; 314(1-2):27-32. PubMed ID: 8957215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory and excitatory effects of micro-, delta-, and kappa-opioid receptor activation on breathing in awake turtles, Trachemys scripta.
    Johnson SM; Kinney ME; Wiegel LM
    Am J Physiol Regul Integr Comp Physiol; 2008 Nov; 295(5):R1599-612. PubMed ID: 18784338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of Kappa Opioid Receptor Inactivation Depends on Sex and Cellular Site of Antagonist Action.
    Reichard KL; Newton KA; Rivera ZMG; Sotero de Menezes PM; Schattauer SS; Land BB; Chavkin C
    Mol Pharmacol; 2020 Nov; 98(5):548-558. PubMed ID: 32913138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys.
    Ko MC; Lee H; Harrison C; Clark MJ; Song HF; Naughton NN; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2003 Jul; 306(1):179-86. PubMed ID: 12676881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
    Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
    Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A mixed opioid agonist with potent antinociceptive activity.
    Gengo PJ; Pettit HO; O'Neill SJ; Wei K; McNutt R; Bishop MJ; Chang KJ
    J Pharmacol Exp Ther; 2003 Dec; 307(3):1221-6. PubMed ID: 14534368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.